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Myasthenia gravis (MG) is an autoimmune neuromuscular 
disorder characterised by a fluctuant variable weakness. In 90% 
of cases antibodies against the nicotinic acetylcholine receptor 
(AchRAb) are pathogenetic: they reduce acetylcholine recep-
tors (AChR) number and impair their function at the neuromus-
cular endplate. The main feature is a variable weakness of the 
skeletal muscles that may involve different muscle districts (oc-
ular, bulbar, limbs). Symptoms are worse in the evening or after 
prolonged exercise and can be reduced by rest. The diagnosis 
is based on a detailed clinical history, on pharmacological tests 
and measurement of AchR-Ab.
To  evaluate  the  clinical  features,  the  diagnosis  and  the 
therapeutic response in 297 myasthenic patients collected in our 
Neuromuscular Centre Database. Knowledge of the prognostic 
factors may help to understand the course of MG and optimize 
its management.
We carried out a study in 297 MG patients followed at the 
Clinical Centre for Neuromuscular diseases of Padua and of 
Santa Chiara Hospital, in Trento. In a database we collected gen-
eral and demographic information, diagnostic tests, clinical data 
about onset, age and type of thymectomy, therapy and clinical 
status at the last follow-up visit. For all the measured parameters 
the Myasthenia Gravis Foundation of America (MGFA) classifi-
cation has been used. Finally we did a statistic analysis.
We consider 177 females and 120 males. The mean age at on-
set was 47 ± 20 years and it results significantly inferior in female 
respect male (p < 0.00001). The late onset group was the largest 
(28%). Thymectomy was performed in 52% of patients. The mean 
time of follow-up was 9 ± 8.6 years; 40% had relapses during the 
disease; the presence of relapses results significantly associated to 
MG class. At last visit 64.9% of patients were improved: 10.4% 
in remission. We find a significant association between clinical 
improvement and MG class (p = 0.001), MGFA score at onset 
(p = 0.00004) and thymectomy (p = 0.005). In 71.1% of cases the 
diagnosis was made at the onset of the disease; in the other patients 
there is an average diagnostic delay of 2.6 ± 3.8 years. The age at 
onset wasn’t significant associated to outcome; the delay results 
significantly associated to MG class (Kruskal Wallis p = 0.02) and 
to clinical outocme (Kruskal Wallis p = 0.03).
We analysed a large series of patients from 2 differents 
hospitals, and we consider disease aspects. From ours studies it 
results that clinical outcomes depends on MG class, on thymec-
tomy, use of immunomodulant therapy and diagnostic delay. 
Sex, age at onset and presence of other autoimmune disease 
don’t seem to be significantly associated to outcome.
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To report two sisters with a metabolic myopathy due to 
muscle carnitine deficiency.
The younger sister was a 22 year-old extremely thin and 
weak girl, that since two years presented progressive up-
per and lower girdle, neck and trunk weakness, myalgias, 
exercise  intolerance,  episodes  of  hypoglycemia  (31  mg/
dl), vomiting, loss of body weight (10 kg), high CK levels 
(15.000 U/L); she was fed by nasogastric tube and became 
virtually  quadriplegic.  CK  levels  decreased  to  302  U/L, 
whereas aldolase (21.8 U/L) and gamma G-T were elevated. 
Muscle MRI revealed oedema and atrophy of upper girdle 
muscles. A psychiatric examination excluded nervous ano-
rexia. The older sister was 28 year old and since 4 years had a 
progressive lower limb weakness. She received a previous di-
agnosis of polymyositis, though she did not respond to IVIg, 
methotrexate or steroids. Muscle biopsy was investigated by 
appropriate  morphological  and  biochemical  investigations. 
Acyl-carnitines were analyzed in serum by radiochemical as-
say and their profile was investigated by mass spectroscopy; 
no organic acidemia was found.
In both sisters muscle biopsy showed a lipid storage my-
opathy (LSM). In the younger sister total carnitine deficiency 
was found both in plasma (15% of control mean) and in muscle 
(30% of control). Free carnitine was also reduced in plasma 3.34 
nMol/ml (normal 27.6-61.9). Long chain acyl-carnitines levels 
were normal in both muscle and plasma. In the older sister total 
muscle carnitine levels were reduced (12% of control mean). 
Oral carnitine and riboflavin supplementation in the younger 
sister restored muscle strength, the body weight was increased 
and nasogastric tube was removed.
We show the value of accurate biochemical studies in 
severe  muscle  weakness  of  unexplained  origin  associated 
with LSM. Although in muscle carnitine deficiency the hall-
mark is low carnitine levels with normal acyl-carnitines, in 
the younger sister a low plasma carnitine was also found. The 
clinical phenotype suggests a muscle carnitine deficiency but 
biochemical studies are compatible with a systemic inherited 
carnitine defect.
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